Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)
Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the safety, tolerability, and efficacy of adding
MK-1029 to montelukast in adults with persistent asthma that is uncontrolled while receiving
montelukast alone. Participants will have a specific genetic marker for clinical efficacy of
MK-1029. The primary hypothesis is that when added to montelukast, treatment with MK-1029 is
superior to placebo, as demonstrated by an increase in forced expiratory volume in one second
(FEV1), measured as the average change from baseline at the end of Week 4 and Week 6 of
treatment.